Medulloblastoma Explained

Medulloblastoma
Field:Neuro-oncology, neurosurgery
Symptoms:Headaches
Nausea
Vomiting
Tiredness
Clumsiness
Dizziness
Change in vision
Handwriting problems[1]
Onset:Between 5 and 9 years old
Prognosis:Five-year survival rate

72.1%[2]

Frequency:About 500 children diagnosed annually in the United States

Medulloblastoma is a common type of primary brain cancer in children. It originates in the part of the brain that is towards the back and the bottom, on the floor of the skull, in the cerebellum, or posterior fossa.[3]

The brain is divided into two main parts, the larger cerebrum on top and the smaller cerebellum below towards the back. They are separated by a membrane called the tentorium. Tumors that originate in the cerebellum or the surrounding region below the tentorium are, therefore, called infratentorial.

Historically, medulloblastomas have been classified as a primitive neuroectodermal tumor (PNET), but it is now known that medulloblastoma is distinct from supratentorial PNETs and they are no longer considered similar entities.[4]

Medulloblastomas are invasive, rapidly growing tumors that, unlike most brain tumors, spread through the cerebrospinal fluid and frequently metastasize to different locations along the surface of the brain and spinal cord. Metastasis all the way down to the cauda equina at the base of the spinal cord is termed "drop metastasis".

The cumulative relative survival rate for all age groups and histology follow-up was 60%, 52%, and 47% at 5 years, 10 years, and 20 years, respectively, with children doing better than adults.

Signs and symptoms

Signs and symptoms are mainly due to secondary increased intracranial pressure due to blockage of the fourth ventricle and tumors are usually present for 1 to 5 months before diagnosis is made. The child typically becomes listless, with repeated episodes of vomiting, and a morning headache, which may lead to a misdiagnosis of gastrointestinal disease or migraine.[5] Soon after, the child will develop a stumbling gait, truncal ataxia, frequent falls, diplopia, papilledema, and sixth cranial nerve palsy. Positional vertigo and nystagmus are also frequent, and facial sensory loss or motor weakness may be present. Decerebrate attacks appear late in the disease.

Extraneural metastasis to the rest of the body is rare, and when it occurs, it is in the setting of relapse, more commonly in the era prior to routine chemotherapy.

Pathogenesis

Medulloblastomas are usually found in the vicinity of the fourth ventricle, between the brainstem and the cerebellum. Tumors with similar appearance and characteristics originate in other parts of the brain, but they are not identical to medulloblastoma.[6]

Although medulloblastomas are thought to originate from immature or embryonal cells at their earliest stage of development, the cell of origin depends on the subgroup of medulloblastoma. WNT tumors originate from the lower rhombic lip of the brainstem, while SHH tumors originate from the external granular layer.[7]

Currently, medulloblastomas are thought to arise from cerebellar stem cells that have been prevented from dividing and differentiating into their normal cell types. This accounts for the histologic variants seen on biopsy. Both perivascular pseudorosette and Homer Wright pseudorosette formations are highly characteristic of medulloblastomas and are seen in up to half of cases.[8] The classic rosette with tumor cells around a central lumen can be seen.[9]

In the past, medulloblastoma was classified using histology, but integrated genomic studies have revealed that medulloblastoma is composed of four distinct molecular and clinical variants termed WNT/β-catenin, Sonic Hedgehog, Group 3, and Group 4.[10] Of these subgroups, WNT patients have an excellent prognosis and group 3 patients have a poor prognosis. Also, a subgroup-specific alternative splicing further confirms the existence of distinct subgroups and highlights the transcriptional heterogeneity between subgroups.[11] Amplification of the Sonic Hedgehog pathway is the best characterized subgroup, with 25% of human tumors having mutations in Patched, Sufu (Suppressor of Fused Homolog), Smoothened, or other genes in this pathway.[12] [13] Medulloblastomas are also seen in Gorlin syndrome as well as Turcot syndrome. Recurrent mutations in the genes CTNNB1, PTCH1, MLL2, SMARCA4, DDX3X, CTDNEP1, KDM6A, and TBR1 were identified in individuals with medulloblastoma.[14] Additional pathways disrupted in some medulloblastomas include MYC, Notch, BMP, and TGF-β signaling pathways.[5] [15] [16] [17] [18] [3]

Diagnosis

The tumor is distinctive on T1- and T2-weighted MRI with heterogeneous enhancement and a typical location adjacent to and extension into the fourth ventricle. Histologically, the tumor is solid, pink-gray in color, and is well circumscribed. The tumor is very cellular, with high mitotic activity, little cytoplasm, and a tendency to form clusters and rosettes.

The Chang staging system can be used in making the diagnosis.[19]

DNA methylation profiling of medulloblastoma allows robust sub-classification and improved outcome prediction using formalin-fixed biopsies. [20]

Correct diagnosis of medulloblastoma may require ruling out atypical teratoid rhabdoid tumor.[21]

Treatment

Treatment begins with maximal surgical removal of the tumor. The addition of radiation to the entire neuraxis and chemotherapy may increase the disease-free survival. This combination may permit a 5-year survival in more than 80% of cases. Some evidence indicates that proton beam irradiation reduces the impact of radiation on the cochlear and cardiovascular areas and reduces the cognitive late effects of cranial irradiation.[22] [23]

The presence of desmoplastic features such as connective tissue formation offers a better prognosis. Prognosis is worse if the child is less than 3 years old, degree of resection is inadequate, or if any CSF, spinal, supratentorial, or systemic spread occurs. Dementia after radiotherapy and chemotherapy is a common outcome appearing two to four years following treatment. Side effects from radiation treatment can include cognitive impairment, psychiatric illness, bone growth retardation, hearing loss, and endocrine disruption.[15] Increased intracranial pressure may be controlled with corticosteroids or a ventriculoperitoneal shunt. An approach to monitor tumor development and treatment response by liquid biopsy is promising, but remains challenging.[24]

Chemotherapy

Chemotherapy is often used as part of treatment. Evidence of benefit, however, is not clear as of 2013.[25] A few different chemotherapeutic regimens for medulloblastoma are used; most involve a combination of lomustine, cisplatin, carboplatin, vincristine, or cyclophosphamide. In younger patients (less than 3–4 years of age), chemotherapy can delay, or in some cases possibly even eliminate, the need for radiotherapy. However, both chemotherapy and radiotherapy often have long-term toxicity effects, including delays in physical and cognitive development, higher risk of second cancers, and increased cardiac disease risks.[26] [27]

Outcomes

Array-based karyotyping of 260 medulloblastomas resulted in the following clinical subgroups based on cytogenetic profiles:[28]

Transcriptional profiling shows the existence of four main subgroups (Wnt, Shh, Group 3, and Group 4).[10]

Survival

The historical cumulative relative survival rate for all age groups and histology follow-up was 60%, 52%, and 47% at 5 years, 10 years, and 20 years, respectively. Patients diagnosed with a medulloblastoma or PNET are 50 times more likely to die than a matched member of the general population.A population-based (SEER) 5-year relative survival rates indicated 69% overall: 72% in children (1–9 years) and 67% in adults (20+ years). The 20-year survival rate is 51% in children. Children and adults have different survival profiles, with adults faring worse than children only after the fourth year after diagnosis (after controlling for increased background mortality). Before the fourth year, survival probabilities are nearly identical.[29] Long-term sequelae of standard treatment include hypothalamic-pituitary and thyroid dysfunction and intellectual impairment. The hormonal and intellectual deficits created by these therapies causes significant impairment of the survivors.[30]

In current clinical studies, the patients are divided into low-, standard- and high-risk groups:

Epidemiology

Medulloblastomas affect just under two people per million per year, and affect children 10 times more than adults.[35] Medulloblastoma is the second-most frequent brain tumor in children after pilocytic astrocytoma[36] and the most common malignant brain tumor in children, comprising 14.5% of newly diagnosed brain tumors.[37] In adults, medulloblastoma is rare, comprising fewer than 2% of CNS malignancies.[38]

The rate of new cases of childhood medulloblastoma is higher in males (62%) than females (38%), a feature that is not seen in adults.[35] [39] Medulloblastoma and other PNET`s are more prevalent in younger children than older children. About 40% of medulloblastoma patients are diagnosed before the age of five, 31% are between the ages of 5 and 9, 18.3% are between the ages of 10 and 14, and 12.7% are between the ages of 15 and 19.[40]

Research models

Using gene transfer of SV40 large T-antigen in neuronal precursor cells of rats, a brain tumor model was established. The PNETs were histologically indistinguishable from the human counterparts and have been used to identify new genes involved in human brain tumor carcinogenesis.[41] The model was used to confirm p53 as one of the genes involved in human medulloblastomas, but since only about 10% of the human tumors showed mutations in that gene, the model can be used to identify the other binding partners of SV40 Large T- antigen, other than p53.[42] [43] In a mouse model, high medulloblastoma frequency appears to be caused by the down regulation of Cxcl3, with Cxcl3 being induced by Tis21.[44] Consistently, the treatment with Cxcl3 completely prevents the growth of medulloblastoma lesions in a Shh-type mouse model of medulloblastoma.[45] Thus, CXCL3 is a target for medulloblastoma therapy.

External links

Notes and References

  1. Web site: Medulloblastoma. St. Jude Children's Research Hospital. March 8, 2023.
  2. Web site: Medulloblastoma Diagnosis and Treatment. National Cancer Institute. 17 September 2018. March 8, 2023.
  3. Book: Roussel MF, Hatten ME . Cerebellum development and medulloblastoma . Cerebellum . 94 . 235–82 . 2011 . 21295689 . 3213765 . 10.1016/B978-0-12-380916-2.00008-5 . 9780123809162 . Current Topics in Developmental Biology .
  4. Book: Hinz . Chris . Hesser . Deneen . vanc . Focusing On Brain Tumors: Medulloblastoma . 2006 . American Brain Tumor Association . 0-944093-67-1 . 2007-03-09 . https://web.archive.org/web/20080908050856/http://hope.abta.org/mdl . 2008-09-08 . dead .
  5. Polkinghorn WR, Tarbell NJ . Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification . Nature Clinical Practice. Oncology . 4 . 5 . 295–304 . May 2007 . 17464337 . 10.1038/ncponc0794 . 24461280 .
  6. Web site: Roger . Packer . vanc . Medulloblastoma . Clinical Trials and Noteworthy Treatments for Brain Tumors . 2002 .
  7. Web site: Medulloblastoma. The Lecturio Medical Concept Library . 10 August 2021.
  8. Book: White . Lucile E. . Levy . Ross M. . Alam . Murad . Ch. 127. Neoplasias and Hyperplasias of Muscular and Neural Origin . http://www.accessmedicine.com/content.aspx?aID=2983360 . Wolff K, Goldsmith LA, Katz SI, Gilchrest B, Paller AS, Leffell DJ . Fitzpatrick's Dermatology in General Medicine . McGraw-Hill Medical . 2008 . 7e .
  9. Book: Ropper AH, Samuels MA . Ch. 31. Intracranial Neoplasms and Paraneoplastic Disorders . http://www.accessmedicine.com/content.aspx?aID=3637579 . Ropper AH, Samuels MA . Adams and Victor's Principles of Neurology . 9e.
  10. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM . 6 . Molecular subgroups of medulloblastoma: the current consensus . Acta Neuropathologica . 123 . 4 . 465–72 . April 2012 . 22134537 . 3306779 . 10.1007/s00401-011-0922-z .
  11. Dubuc AM, Morrissy AS, Kloosterhof NK, Northcott PA, Yu EP, Shih D, Peacock J, Grajkowska W, van Meter T, Eberhart CG, Pfister S, Marra MA, Weiss WA, Scherer SW, Rutka JT, French PJ, Taylor MD . 6 . Subgroup-specific alternative splicing in medulloblastoma . Acta Neuropathologica . 123 . 4 . 485–499 . April 2012 . 22358458 . 3984840 . 10.1007/s00401-012-0959-7 .
  12. Marino S . Medulloblastoma: developmental mechanisms out of control . Trends in Molecular Medicine . 11 . 1 . 17–22 . January 2005 . 15649818 . 10.1016/j.molmed.2004.11.008 .
  13. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ . 6 . Subtypes of medulloblastoma have distinct developmental origins . Nature . 468 . 7327 . 1095–9 . December 2010 . 21150899 . 3059767 . 10.1038/nature09587 . 2010Natur.468.1095G .
  14. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber UD, Wang Q, Lasitschka B, Bartholomae CC, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts MJ, Russell RB, Coco S, Tonini GP, Schüller U, Hans V, Graf N, Kim YJ, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann MU, Frühwald MC, Hasselblatt M, Jabado N, Rutkowski S, von Bueren AO, Williamson D, Clifford SC, McCabe MG, Collins VP, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott PA, Taylor MD, Meyerson M, Pomeroy SL, Yaspo ML, Korbel JO, Korshunov A, Eils R, Pfister SM, Lichter P . 6 . Dissecting the genomic complexity underlying medulloblastoma . Nature . 488 . 7409 . 100–5 . August 2012 . 22832583 . 3662966 . 10.1038/nature11284 . 2012Natur.488..100J .
  15. Ellison DW . Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease . Acta Neuropathologica . 120 . 3 . 305–16 . September 2010 . 20652577 . 10.1007/s00401-010-0726-6 . 29093769 .
  16. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL . 6 . Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome . Journal of Clinical Oncology . 29 . 11 . 1424–30 . April 2011 . 21098324 . 3082983 . 10.1200/JCO.2010.28.5148 .
  17. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A, Cavalli FM, Wang X, Remke M, Wu X, Chiu RY, Chu A, Chuah E, Corbett RD, Hoad GR, Jackman SD, Li Y, Lo A, Mungall KL, Nip KM, Qian JQ, Raymond AG, Thiessen NT, Varhol RJ, Birol I, Moore RA, Mungall AJ, Holt R, Kawauchi D, Roussel MF, Kool M, Jones DT, Witt H, Fernandez-L A, Kenney AM, Wechsler-Reya RJ, Dirks P, Aviv T, Grajkowska WA, Perek-Polnik M, Haberler CC, Delattre O, Reynaud SS, Doz FF, Pernet-Fattet SS, Cho BK, Kim SK, Wang KC, Scheurlen W, Eberhart CG, Fèvre-Montange M, Jouvet A, Pollack IF, Fan X, Muraszko KM, Gillespie GY, Di Rocco C, Massimi L, Michiels EM, Kloosterhof NK, French PJ, Kros JM, Olson JM, Ellenbogen RG, Zitterbart K, Kren L, Thompson RC, Cooper MK, Lach B, McLendon RE, Bigner DD, Fontebasso A, Albrecht S, Jabado N, Lindsey JC, Bailey S, Gupta N, Weiss WA, Bognár L, Klekner A, Van Meter TE, Kumabe T, Tominaga T, Elbabaa SK, Leonard JR, Rubin JB, Liau LM, Van Meir EG, Fouladi M, Nakamura H, Cinalli G, Garami M, Hauser P, Saad AG, Iolascon A, Jung S, Carlotti CG, Vibhakar R, Ra YS, Robinson S, Zollo M, Faria CC, Chan JA, Levy ML, Sorensen PH, Meyerson M, Pomeroy SL, Cho YJ, Bader GD, Tabori U, Hawkins CE, Bouffet E, Scherer SW, Rutka JT, Malkin D, Clifford SC, Jones SJ, Korbel JO, Pfister SM, Marra MA, Taylor MD . 6 . Subgroup-specific structural variation across 1,000 medulloblastoma genomes . Nature . 488 . 7409 . 49–56 . August 2012 . 22832581 . 3683624 . 10.1038/nature11327 . 2012Natur.488...49N .
  18. Hatten ME, Roussel MF . Development and cancer of the cerebellum . Trends in Neurosciences . 34 . 3 . 134–42 . March 2011 . 21315459 . 3051031 . 10.1016/j.tins.2011.01.002 .
  19. Web site: Allaham H . Medulloblastoma staging . wikidoc .
  20. Schwalbe EC, Williamson D, Lindsey JC, Hamilton D, Ryan SL, Megahed H, Garami M, Hauser P, Dembowska-Baginska B, Perek D, Northcott PA, Taylor MD, Taylor RE, Ellison DW, Bailey S, Clifford SC . DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies . Acta Neuropathol . 125 . 3 . 359–71 . March 2013 . 23291781 . 4313078 . 10.1007/s00401-012-1077-2 .
  21. Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, Duffner PK, Kun LE, Perlman EJ . 6 . Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study . The American Journal of Surgical Pathology . 22 . 9 . 1083–92 . September 1998 . 9737241 . 10.1097/00000478-199809000-00007 .
  22. Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U . Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function . Pediatric Blood & Cancer . 51 . 1 . 110–7 . July 2008 . 18306274 . 10.1002/pbc.21530 . 36735536 .
  23. Blomstrand M, Brodin NP, Munck Af Rosenschöld P, Vogelius IR, Sánchez Merino G, Kiil-Berthlesen A, Blomgren K, Lannering B, Bentzen SM, Björk-Eriksson T . 6 . Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma . Neuro-Oncology . 14 . 7 . 882–9 . July 2012 . 22611031 . 3379806 . 10.1093/neuonc/nos120 .
  24. Eibl RH, Schneemann, M . Liquid biopsy for monitoring medulloblastoma. . Extracell Vesicles Circ Nucleic Acids . 3 . 263–74 . Sep 2022 . 3 . 10.20517/evcna.2022.36 . 252638651 . free .
  25. Michiels EM, Schouten-Van Meeteren AY, Doz F, Janssens GO, van Dalen EC . Chemotherapy for children with medulloblastoma . The Cochrane Database of Systematic Reviews . 1 . CD006678 . January 2015 . 1 . 25879092 . 10.1002/14651858.CD006678.pub2 . 10651941 .
  26. Fossati P, Ricardi U, Orecchia R . Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy . Cancer Treatment Reviews . 35 . 1 . 79–96 . February 2009 . 18976866 . 10.1016/j.ctrv.2008.09.002 .
  27. Crawford JR, MacDonald TJ, Packer RJ . Medulloblastoma in childhood: new biological advances . The Lancet. Neurology . 6 . 12 . 1073–85 . December 2007 . 18031705 . 10.1016/S1474-4422(07)70289-2 . 13013757 .
  28. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A . 6 . Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci . Journal of Clinical Oncology . 27 . 10 . 1627–36 . April 2009 . 19255330 . 10.1200/JCO.2008.17.9432 . 21794571 . free .
  29. Smoll NR . Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs) . Cancer . 118 . 5 . 1313–22 . March 2012 . 21837678 . 10.1002/cncr.26387 . 8490276 . free .
  30. Web site: Medulloblastoma . Roger J. . Packer . 2010 . 2015-02-22 . 2017-11-07 . https://web.archive.org/web/20171107011636/http://www.childhoodbraintumor.org/medical-information/brain-tumor-types-and-imaging/item/88-updated-2010 . dead .
  31. Web site: Identifying Low-Risk Medulloblastoma to De-escalate Therapy. Medscape. 2020-01-03.
  32. Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Björk-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R . 6 . Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial . Journal of Clinical Oncology . 30 . 26 . 3187–93 . September 2012 . 22851561 . 10.1200/JCO.2011.39.8719 . free .
  33. Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R, Massimino M, Navajas A, von Hoff K, Rutkowski S, Warmuth-Metz M, Clifford SC, Pietsch T, Pizer B, Lannering B . 6 . Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study . Journal of Neuro-Oncology . 129 . 3 . 515–524 . September 2016 . 27423645 . 5020107 . 10.1007/s11060-016-2202-1 .
  34. Jakacki RI, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A, Goldwein J, Mehta M, Packer RJ, Tarbell N, Fitz C, Vezina G, Hilden J, Pollack IF . 6 . Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study . Journal of Clinical Oncology . 30 . 21 . 2648–53 . July 2012 . 22665539 . 4559602 . 10.1200/JCO.2011.40.2792 .
  35. Smoll NR, Drummond KJ . The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children . Journal of Clinical Neuroscience . 19 . 11 . 1541–4 . November 2012 . 22981874 . 10.1016/j.jocn.2012.04.009 . 7922631 .
  36. Web site: Chapter 7: Tumors of the Central Nervous System . https://web.archive.org/web/20120312041034/http://neuropathology-web.org/chapter7/chapter7cMedulloblastoma.html . 12 March 2012 . Neuropathology . NEOMED .
  37. Book: Gurney . James G. . Smith . Malcolm A. . Bunin . Greta R. . CNS and Miscellaneous Intracranial and Intraspinal Neoplasms . http://seer.cancer.gov/publications/childhood/cns.pdf . PDF . Ries LA, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR . Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995 . National Cancer Institute . Bethesda MD . 1999 . NIH Pub. No. 99-4649 .
  38. Web site: Selected Primary Brain and Central Nervous System Tumor Age-Specific Incidence Rates . Central Brain Tumor Registry of the United States, 1998–2002 . 2007-03-09 . 2007-09-27 . https://web.archive.org/web/20070927210152/http://cbtrus.org/2005-2006/tables/2006.table12.pdf . dead .
  39. Web site: Selected Childhood Primary Brain and Central Nervous System Tumor Incidence Rates by Major Histology Groupings, Histology and Gender . Central Brain Tumor Registry of the United States, 1998–2002 . 2007-03-14 . 2007-09-27 . https://web.archive.org/web/20070927210105/http://cbtrus.org/2005-2006/tables/2006.table13.pdf . dead .
  40. Web site: Selected Childhood Primary Brain and Central Nervous System Tumor Age-Specific Incidence Rates . Central Brain Tumor Registry of the United States, 1998–2002 . 2007-03-14 . 2007-09-27 . https://web.archive.org/web/20070927210146/http://cbtrus.org/2005-2006/tables/2006.table15.pdf . dead .
  41. Eibl RH, Kleihues P, Jat PS, Wiestler OD . A model for primitive neuroectodermal tumors in transgenic neural transplants harboring the SV40 large T antigen . The American Journal of Pathology . 144 . 3 . 556–64 . March 1994 . 8129041 . 1887088 .
  42. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P . p53 mutations in nonastrocytic human brain tumors . Cancer Research . 51 . 22 . 6202–5 . November 1991 . 1933879 .
  43. Eibl RH, Schneemann M . From TP53 Mutations to Molecular Classification and Liquid Biopsy . Biology . 12 . 2 . 267 . February 2023 . 10.3390/biology12020267 . 36829544 . 9952923 . free .
  44. Farioli-Vecchioli S, Cinà I, Ceccarelli M, Micheli L, Leonardi L, Ciotti MT, De Bardi M, Di Rocco C, Pallini R, Cavallaro S, Tirone F . 6 . Tis21 knock-out enhances the frequency of medulloblastoma in Patched1 heterozygous mice by inhibiting the Cxcl3-dependent migration of cerebellar neurons . The Journal of Neuroscience . 32 . 44 . 15547–64 . October 2012 . 23115191 . 6621585 . 10.1523/JNEUROSCI.0412-12.2012 .
  45. Ceccarelli M, Micheli L, Tirone F . Suppression of Medulloblastoma Lesions by Forced Migration of Preneoplastic Precursor Cells with Intracerebellar Administration of the Chemokine Cxcl3 . Frontiers in Pharmacology . 7 . 484 . 2016 . 28018222 . 5159413 . 10.3389/fphar.2016.00484 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Medulloblastoma".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.